| [1] |
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet, 2020, 395(10225): 709-733.
|
| [2] |
Yuan J, Zou XR, Han SP, et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE) [J]. BMC Nephrol, 2017, 18(1): 23.
|
| [3] |
Gregg LP, Hedayati SS. Management of traditional cardiovascular risk factors in CKD: what are the data? [J]. Am J Kidney Dis, 2018, 72(5): 728-744.
|
| [4] |
Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy [J]. Lancet, 2017, 390(10105): 1888-1917.
|
| [5] |
Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review [J]. J Am Coll Cardiol, 2019, 74(14): 1823-1838.
|
| [6] |
Nicolas J, Claessen B, Mehran R. Implications of kidney disease in the cardiac patient [J]. Interv Cardiol Clin, 2020, 9(3): 265-278.
|
| [7] |
Parnham SF, Gleadle JM, De Pasquale CG, et al. Myocardial ischemia assessment in chronic kidney disease: challenges and pitfalls [J]. Front Cardiovasc Med, 2014, 1: 13.
|
| [8] |
Kadatz MJ, Lee ES, Levin A. Predicting progression in CKD: perspectives and precautions [J]. Am J Kidney Dis, 2016, 67(5): 779-786.
|
| [9] |
Gregg LP, Adams-Huet B, Li X, et al. Effect modification of chronic kidney disease on the association of circulating and imaging cardiac biomarkers with outcomes [J]. J Am Heart Assoc, 2017, 6(7): e005235.
|
| [10] |
Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC) [J]. BMC Nephrol, 2013, 14: 229.
|
| [11] |
Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2011, 32(23): 2999-3054.
|
| [12] |
Colbert G, Jain N, de Lemos JA, et al. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD [J]. Clin J Am Soc Nephrol, 2015, 10(3): 515-529.
|
| [13] |
Masakane I, Sakurai K. Current approaches to middle molecule removal: room for innovation [J]. Nephrol Dial Transplant, 2018, 33(Suppl 3): iii12-iii21.
|
| [14] |
Velasquez MT, Centron P, Barrows I, et al. Gut microbiota and cardiovascular uremic toxicities [J]. Toxins (Basel), 2018, 10(7): 287.
|
| [15] |
Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells [J]. Kidney Int, 2006, 69(10): 1780-1785.
|
| [16] |
Dou L, Jourde-Chiche N, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells [J]. J Thromb Haemost, 2007, 5(6): 1302-1308.
|
| [17] |
Liu WC, Tomino Y, Lu KC. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120 [J]. Toxins (Basel), 2018, 10(9): 367.
|
| [18] |
Watanabe K, Watanabe T, Nakayama M. Cerebro-renal interactions: impact of uremic toxins on cognitive function [J]. Neurotoxicology, 2014, 44: 184-193.
|
| [19] |
Guo C, Rao XR. Understanding and therapeutic strategies of chinese medicine on gut-derived uremic toxins in chronic kidney disease [J]. Chin J Integr Med, 2018, 24(6): 403-405.
|
| [20] |
Hoyer FF, Nahrendorf M. Uremic toxins activate macrophages [J]. Circulation, 2019, 139(1): 97-100.
|
| [21] |
Raggi P. Cardiovascular disease: coronary artery calcification predicts risk of CVD in patients with CKD [J]. Nat Rev Nephrol, 2017, 13(6): 324-326.
|
| [22] |
Pugliese G, Iacobini C, Blasetti Fantauzzi C, et al. The dark and bright side of atherosclerotic calcification [J]. Atherosclerosis, 2015, 238(2): 220-230.
|
| [23] |
Takayama Y, Yasuda Y, Suzuki S, et al. Relationship between abdominal aortic and coronary artery calcification as detected by computed tomography in chronic kidney disease patients [J]. Heart Vessels, 2016, 31(7): 1030-1037.
|
| [24] |
Lankinen R, Hakamäki M, Metsärinne K, et al. Cardiovascular determinants of mortality in advanced chronic kidney disease [J]. Am J Nephrol, 2020, 51(9): 726-735.
|
| [25] |
Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography [J]. J Am Coll Cardiol, 2013, 62(19): 1748-1758.
|
| [26] |
Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture [J]. Circ Res, 2014, 114(12): 1852-1866.
|
| [27] |
Libby P. Superficial erosion and the precision management of acute coronary syndromes: not one-size-fits-all [J]. Eur Heart J, 2017, 38(11): 801-803.
|
| [28] |
Querfeld U, Mak RH, Pries AR. Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity [J]. Clin Sci (Lond), 2020, 134(12): 1333-1356.
|
| [29] |
Lockhart CJ, Hamilton PK, Quinn CE, et al. End-organ dysfunction and cardiovascular outcomes: the role of the microcirculation [J]. Clin Sci (Lond), 2009, 116(3): 175-190.
|
| [30] |
Charytan DM, Padera R, Helfand AM, et al. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease [J]. Int J Cardiol, 2014, 176(1): 99-109.
|
| [31] |
Bangalore S, Maron DJ, O′Brien SM, et al. Management of coronary disease in patients with advanced kidney disease [J]. N Engl J Med, 2020, 382(17): 1608-1618.
|
| [32] |
Spertus JA, Jones PG, Maron DJ, et al. Health status after invasive or conservative care in coronary and advanced kidney disease [J]. N Engl J Med, 2020, 382(17): 1619-1628.
|
| [33] |
Herrington WG, Staplin N. In patients with coronary disease and CKD, initial invasive therapy did not improve angina-related health status [J]. Ann Intern Med, 2020, 173(4): JC17.
|